Results 161 to 170 of about 51,875 (217)

Cost-effectiveness of latent tuberculosis infection screening using interferon-gamma release assays among migrants to Japan: a Markov modelling study incorporating social vulnerability and access barriers. [PDF]

BMJ Open
Kowada A.
europepmc   +1 more source

Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models. [PDF]

Nat Commun
Ruiz-Gonzalez CE, Singh M, Masias-Leon Y, Chen X, Sarhan MO, Martinez-Martinez YB, Patel S, Shambles M, Villabona-Rueda A, Lissit K, Tweedie D, Scerba MT, Bishai WR, Artemov D, Xu JC, D'Alessio F, Hafner R, Greig NH, Manion M, Sereti I, Jain SK.   +20 more
europepmc   +1 more source

Rapid-onset massive immune-mediated pericardial effusion in a patient with anti-IFN-γ autoantibodies syndrome. [PDF]

Front Immunol
Chen F, Ning Y, Liang H, Qin J, Liang S, Huang X, Liang X, Tan F, Chen N, Wu S, Hong L, He Z, Feng T.   +12 more
europepmc   +1 more source

[Rifampin].

Postepy biochemii, 1973
openaire   +1 more source

Clarifications in JAMA Clinical Guidelines Synopsis.

JAMA
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rifampin

American Journal of Health-System Pharmacy, 1972
Rifampin is a potent antituberculous drug. In the treatment of drug-resistant tuberculosis it is highly effective provided it is given in combination with other drugs to which the patient's organisms are sensitive. Rifampin and ethambutol is a particularly powerful combination and will achieve almost 100% sputum conversion.
M, Schonell, E, Dorken, S, Grzybowski
openaire   +4 more sources